Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models

Antiviral Chemistry and Chemotherapy

Volumn 15, Issue 2, 2004, Pages 101-109

  Morrey, John D ^a   Day, Craig W ^a   Julander, Justin G ^a   Blatt, Lawrence M ^b   Smee, Donald F ^a   Sidwell, Robert W ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b InterMune Inc   (United States)

Author keywords

Antiviral; Flavivirus; Hamster; Interferon alpha; Mouse; Ribavirin; West Nile virus

Indexed keywords

ALPHA INTERFERON; AMPLIGEN; CONSENSUS INTERFERON; IMIQUIMOD; INTERFERON INDUCING AGENT; RIBAVIRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SYRIAN HAMSTER; VIREMIA; WEIGHT GAIN; WEST NILE FLAVIVIRUS;

AMINOQUINOLINES; ANIMALS; CELLS, CULTURED; CRICETINAE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; INTERFERON INDUCERS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-ALPHA; INTERFERONS; MICE; MICE, INBRED BALB C; MOTOR ACTIVITY; POLY I-C; POLY U; RIBAVIRIN; SURVIVAL RATE; TIME FACTORS; WEST NILE FEVER; WEST NILE VIRUS;

EID: 2342506498     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Agrawal AG (2003) Human immunoglobulin as a treatment for West Nile virus infection. Journal of Infectious Diseases 188:1-4.
2. Anderson JF & Rahal JJ (2002) Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerging Infectious Diseases 8:107-108.
3. Blatt LM, Davis JM, Klein SB & Taylor MW (1996) The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. Journal of Interferon & Cytokine Research 16:489-499.
4. Brooks TJ & Phillpotts RJ (1999) Interferon-alpha protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes. Antiviral Research 41:57-64.
5. Buates S & Matlashewski G (1999) Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. Journal of Infectious Diseases 179:1485-1494.
6. CDC (1999) Outbreak of West Nile-like viral encephalitis- New York, 1999. MMWR. Morbidity & Mortality Weekly Report. 48:845-849.
7. CDC (2002). Provisional surveillance summary of the West Nile virus Epidemic-United States, January-November 2002 MMWR. Morbidity & Mortality Weekly Report. 51:1129-11333.
8. Chowers MY, Lang R, Nassar F, Ben-David D, Giladi M, Rubinshtein E, Itzhaki A, Mishal J, Siegman-Igra Y, Kitzes R, Pick N, Landau Z, Wolf D, Bin H, Mendelson E, Pitlik SD & Weinberger M (2001) Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerging Infectious Diseases 7:675-678.
9. Diamond MS & Harris E (2001) Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism. Virology 289:297-311.
10. Fish EN, Banerjee K, Levine HL & Stebbing N (1986) Antiherpetic effects of a human alpha interferon analog, IFN-alpha Con1, in hamsters. Antimicrobial Agents & Chemotherapy 30:52-56.
11. Gangemi JD, Lazdins J, Dietrich FM, Matter A, Poncioni B & Hochkeppel HK (1989a) Antiviral activity of a novel recombinant human interferon-alpha B/D hybrid. Journal of Interferon Research 9:227-237.
12. Gangemi JD, Matter A, Poncioni B & Hochkeppel HK (1989b) Significant differences in therapeutic responses to a human interferon-alpha B/D hybrid in Rauscher or Friend murine leukemia virus infections. Journal of Interferon Research 9:275-283.
13. Haahr S (1968) The occurrence of virus and interferon in the spleen, serum and brain in mice after experimental infections with West Nile virus. Acta Pathologica et Microbiologica Scandinavica 74:445-457.
14. Haahr S (1971) The influence of Poly I:C on the course of infection in mice inoculated with West Nile virus. Arch Gesamte Virusforsch 35:1-9.
15. Harinasuta C, Wasi C & Vithanomsat S (1984) The effect of interferon on Japanese encephalitis virus in vitro. Southeast Asian Journal of Tropical Medicine & Public Health 15:564-568.
16. Harrison CJ, Miller RL & Bernstein DI (1994) Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrobial Agents & Chemotherapy 38:2059-2064.
17. He Y & Katze MG (2002) To interfere and to anti-interfere: the interplay between hepatitis C virus and interferon. Viral Immunology 15:95-119.
18. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K & Akira S (2002) Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunology 3:196-200.
19. Knudsen TB, Andersen O & Kronborg G (2003) Death from the Nile crosses the Atlantic: the West Nile Fever story. Scandinavian Journal of Infectious Diseases 35:820-825.
20. Lanciotti RS, Ebel GD, Deubel V, Kerst AJ, Murri S, Meyer R, Bowen M, McKinney N, Morrill WE, Crabtree MB, Kramer LD & Roehrig JT (2002) Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East. Virology 298:96-105.
21. Leyssen P, Drosten C, Paning M, Charlier N, Paeshuyse J, De Clercq E & Neyts J (2003) Interferons, interferon inducers, and interferon-ribavirin in treatment of flavivirus-induced encephalitis in mice. Antimicrobial Agents & Chemotherapy 47:777-782.
22. Lin OS & Keeffe EB (2001) Current treatment strategies for chronic hepatitis B and C. Annual Review of Medicine 52:29-49.
23. Lukaszewski RA & Brooks TJ (2000) Pegylated alpha interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on the host immune response to infection. Journal of Virology 74:5006-5015.
24. Melian EB & Plosker GL (2001) Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 61:1661-1691.
25. Merchant RE, McVicar DW, Merchant LH & Young HF (1992) Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial. Journal of Neurooncology 12:75-83.
26. Miller RL, Tomai MA, Harrison CJ & Bernstein DI (2002) Immunomodulation as a treatment strategy for genital herpes: review of the evidence. International Immunopharmacology 2:443-451.
27. Morrey JD, Smee DF, Sidwell RW & Tseng CK (2002) Identification of active compounds against a New York isolate of West Nile virus. Antiviral Research 55:107-116.
28. Petersen LR & Marfin AA (2002) West Nile virus: a primer for the clinician. Annals of Internal Medicine 137:173-179.
29. Provisional surveillance summary of the West Nile virus Epidemic-United States, January-November 2002. (2002) MMWR. Morbidity & Mortality Weekly Report 51:1129-1133.
30. Sidwell RW (1996) Ribavirin: a review of antiviral efficacy, recent research. In Developments in Antimicrobial Agents & Chemotherapy. Edited by G Pandalai. Kerala: Research Signpost. 1:219-255.
31. Sidwell RW & Huffman JH (1971) Use of disposable microtissue culture plates for antiviral and interferon induction studies. Applied Microbiology 22:797-801.
32. Sidwell RW, Huffman JH, Barnard DL, Smee DF, Warren RP, Chirigos MA, Kende M & Huggins J (1994a) Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections. Antiviral Research 25:105-122.
33. Sidwell RW, Morrey JD, Warren RP, Burger RA, Okleberry K, Sim IS & Hitchcock M (1994b) Effect of the combination of human recombinant alpha interferon-A/D and 2′,3′-didehydro=2′,3′ -dideoxythymidine on murine retrovirus disease. In Recent Advances in Chemotherapy. Edited by RW Sidwell, JD Morrey, RP Warren, RA Burger, K Okleberry, IS Sim & M Hitchcock. Washington, DC: American Society for Microbiology, pp. 650-651.
34. Sidwell RW & Smee DF (2002) Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control. Antiviral Research 57:101-111.
35. Sidwell RW, Warren RP, Okleberry K, Burger RA & Morrey JD (1995) Effect of the combination of interferon-alpha and stavudine on Friend virus infections in (B10.A X A.By)F1 mice. Journal of Infectious Diseases 171(Suppl. 2):S93-S98.
36. Singh IP, Coppenhaver DH, Sarzotti M, Sriyuktasuth P, Poast J, Levy HB & Baron S (1989) Postinfection therapy of arbovirus infections in mice. Antimicrobial Agents & Chemotherapy 33:2126-2131.
37. Solomon T, Dung NM, Wills B, Kneen R, Gainsborough M, Diet TV, Thuy TT, Loan HT, Khanh VC, Vaughn DW, White NJ & Farrar JJ (2003) Interferon alfa-2α in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet 361:821-826.
38. Syed TA (2001) A review of the applications of imiquimod: a novel immune response modifier. Expert Opinion on Pharmacotherapy. 2:877-882.
39. Takahashi T, Hosoya M, Kimura K, Ohno K, Mori S, Takahashi K & Shigeta S (1998) The cooperative effect of interferon-alpha and ribavirin on subacute sclerosing panencephalitis (SSPE) virus infections, in vitro and in vivo. Antiviral Research 37:29-35.
40. Taylor JL, Schoenherr C & Grossberg SE (1980) Protection against Japanese encephalitis virus in mice and hamsters by treatment with carboxymethylacridanone, a potent interferon inducer. Journal of Infectious Diseases 142:394-399.
41. Tomoda A, Shiraishi S, Hosoya M, Hamada A & Miike T (2001) Combined treatment with interferon-alpha and ribavirin for subacute sclerosing panencephalitis. Pediatric Neurology 24:54-59.
42. Wintergerst U, Gangemi JD, Whitley RJ, Chatterjee S & Kern ER (1999) Effect of recombinant human interferon alpha B/D (rHu-IFN-alpha B/D) in combination with acyclovir in experimental HSV-1 encephalitis. Antiviral Research 44:75-78.
43. Xiao SY, Guzman H, Zhang H, Travassos da Rosa AP & Tesh RB (2001) West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerging Infectious Diseases 7:714-721.
44. Zorpette G (2000) Biohazards-emerging diseases. A island. Scientific American 282:22-23.